Inventor · disambiguated record
Sangdon Han
Also filed as: HAN SANGDON
41 granted patents·22 pending applications·280 citations·filing 2004–2024
98Inventor score
Files withARENA PHARM INC28CRINETICS PHARMACEUTICALS INC21JONES ROBERT M5CROSSIGNAL THERAPEUTICS INC2TEEGARDEN BRADLEY2
Top patents by PatentIndex Score
63 records- 0197US10981894B2Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2020·Granted Apr 20, 2021·6 cites·20 claims
- 0296US11771695B2Cannabinoid receptor modulatorsARENA PHARM INC·Filed 2021·Granted Oct 3, 2023·4 cites·11 claims
- 0396US11186590B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2020·Granted Nov 30, 2021·6 cites·11 claims
- 0495US11834462B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2022·Granted Dec 5, 2023·2 cites·16 claims
- 0595US10766877B2Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Sep 8, 2020·7 cites·20 claims
- 0695US10604507B2Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Mar 31, 2020·7 cites·20 claims
- 0795US10562884B2Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Feb 18, 2020·7 cites·20 claims
- 0894US11566015B2Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2021·Granted Jan 31, 2023·2 cites·36 claims
- 0994US11560369B2Crystalline forms and processes for the preparation of cannabinoid receptor modulatorsARENA PHARM INC·Filed 2021·Granted Jan 24, 2023·2 cites·20 claims
- 1094US8778950B2Cannabinoid receptor modulatorsJONES ROBERT M·Filed 2010·Granted Jul 15, 2014·21 cites·6 claims
- 1194US8580841B2Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disordersJONES ROBERT M·Filed 2009·Granted Nov 12, 2013·21 cites·51 claims
- 1293US10981895B2Crystalline forms and processes for the preparation of cannabinoid receptor modulatorsARENA PHARM INC·Filed 2018·Granted Apr 20, 2021·4 cites·16 claims
- 1393US10696689B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Jun 30, 2020·12 cites·8 claims
- 1493US10183930B2Crystalline forms and processes for the preparation of cannabinoid receptor modulatorsARENA PHARM INC·Filed 2016·Granted Jan 22, 2019·10 cites·11 claims
- 1593US9896432B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2017·Granted Feb 20, 2018·11 cites·20 claims
- 1693US9458136B2Crystalline forms and processes for the preparation of cannabinoid receptor modulatorsBLACKBURN ANTHONY C·Filed 2012·Granted Oct 4, 2016·11 cites·34 claims
- 1793US9126932B2Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disordersARENA PHARM INC·Filed 2013·Granted Sep 8, 2015·17 cites·61 claims
- 1893US8148417B2Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related theretoTEEGARDEN BRADLEY·Filed 2007·Granted Apr 3, 2012·21 cites·12 claims
- 1992US11214548B2Cannabinoid receptor modulatorsARENA PHARM INC·Filed 2019·Granted Jan 4, 2022·3 cites·8 claims
- 2092US10632134B2Cannabinoid receptor modulatorsARENA PHARM INC·Filed 2017·Granted Apr 28, 2020·5 cites·16 claims
- 2192US10351547B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2017·Granted Jul 16, 2019·9 cites·24 claims
- 2292US9902703B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2016·Granted Feb 27, 2018·8 cites·17 claims
- 2392US9522133B2Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disordersARENA PHARM INC·Filed 2015·Granted Dec 20, 2016·9 cites·42 claims
- 2491US11414397B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2020·Granted Aug 16, 2022·2 cites·23 claims
- 2591US11072598B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Jul 27, 2021·6 cites·20 claims
- 2691US9867822B2Cannabinoid receptor modulatorsARENA PHARM INC·Filed 2016·Granted Jan 16, 2018·7 cites·18 claims
- 2791US9492447B2Cannabinoid receptor modulatorsARENA PHARM INC·Filed 2015·Granted Nov 15, 2016·9 cites·20 claims
- 2891US9328107B2Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related theretoARENA PHARM INC·Filed 2014·Granted May 3, 2016·12 cites·34 claims
- 2991USRE45336EPrimary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related theretoARENA PHARM INC·Filed 2007·Granted Jan 13, 2015·12 cites·22 claims
- 3091US8664258B2Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related theretoTEEGARDEN BRADLEY·Filed 2012·Granted Mar 4, 2014·14 cites·25 claims
- 3189US2025074874A1SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERSARENA PHARM INC·Filed 2024·Application pending·0 cites
- 3288US12479828B2Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2023·Granted Nov 25, 2025·0 cites·22 claims
- 3388US9597340B2Cannabinoid receptor modulatorsTHATTE JAYANT·Filed 2012·Granted Mar 21, 2017·9 cites·17 claims
- 3485US2024109866A1Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3581US9944606B2Cannabinoid receptor modulatorsJONES ROBERT M·Filed 2012·Granted Apr 17, 2018·3 cites·30 claims
- 3681US2023257349A1SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERSARENA PHARM INC·Filed 2022·Application pending·0 cites
- 3780US2022380337A1Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3877US9987252B2Primary amines and derivitves thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related theretoARENA PHARM INC·Filed 2016·Granted Jun 5, 2018·1 cites·15 claims
- 3977US2022306586A1Cannabinoid receptor modulatorsARENA PHARM INC·Filed 2021·Application pending·0 cites
- 4074US11746091B2Cannabinoid receptor modulatorsARENA PHARM INC·Filed 2020·Granted Sep 5, 2023·0 cites·12 claims
- 4174US2022048924A1Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4272US2020407316A1SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERSARENA PHARM INC·Filed 2020·Application pending·0 cites
- 4367US2019135752A1SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERSARENA PHARM INC·Filed 2018·Application pending·0 cites
- 4467US2020069681A1Cannabinoid receptor modulatorsARENA PHARM INC·Filed 2019·Application pending·0 cites
- 4565US2019070149A1Primary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related theretoARENA PHARM INC·Filed 2018·Application pending·0 cites
- 4664US12109219B2Cannabinoid receptor modulatorsARENA PHARM INC·Filed 2020·Granted Oct 8, 2024·0 cites·20 claims
- 4764US2018354907A1Cannabinoid receptor modulatorsARENA PHARM INC·Filed 2018·Application pending·0 cites
- 4863US2018280386A1Cannabinoid receptor modulatorsARENA PHARM INC·Filed 2017·Application pending·0 cites
- 4962US2017217885A1SUBSTITUTED 1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERSARENA PHARM INC·Filed 2016·Application pending·0 cites
- 5057US12065444B2Substituted tetrazolo[1,5-a]pyrazines and tetrazolo[1,5-c]pyrimidines as adenosine receptor antagonistsCROSSIGNAL THERAPEUTICS INC·Filed 2022·Granted Aug 20, 2024·0 cites·18 claims
Showing the top 50 of 63 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Sangdon Han files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →